Fingerprint
Dive into the research topics where Ian Flitcroft is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Global Patterns of Myopia, Age, Sex and Vision Loss: A Comparative Analysis of U.S. and South Korean National Surveys
Moore, M., Loughman, J., Baek, S.-H. & Flitcroft, I., 4 Mar 2026, In: Ophthalmology Science. 2026, 101142.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Letter to the Editor: The limitations of centile curves for evaluating myopic eye growth
Flitcroft, D. I., Lingham, G., Kneepkens, S., Polling, J. R., Klaver, C. & Loughman, J., 1 Feb 2026, In: Optometry and Vision Science. 103, 2, p. e70034Research output: Contribution to journal › Letter › peer-review
-
Low-concentration atropine for management of myopia progression: does iris colour matter?
Lingham, G., Loughman, J., Lee, S. S. Y., Repka, M. X., Kerin, E., Gómez Sánchez, A., Kobia-Acquah, E., Nkansah, E. K., Flitcroft, I. & Mackey, D. A., 2026, (Accepted/In press) In: Eye (Basingstoke). 8 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
MyopiaX-1 Safety and Efficacy of a Novel Approach to Slow Juvenile Myopia Progression: A Multicenter, Randomized, Controlled Trial
MyopiaX-1 Study Group, Jan 2026, In: Ophthalmology Science. 6, 1, 100973.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial
CHAMP trial Group Investigators, 2026, (Accepted/In press) In: Ophthalmic and Physiological Optics. 9 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile